A Phase I Open Label, Dose Escalation Trial Of QPI-1007 Delivered By A Single Intravitreal (IVT) Injection To Subjects With Low Visual Acuity And Acute Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)

Update Item Information
Identifier 20130212_nanos_sciplatform2_01-1
Title A Phase I Open Label, Dose Escalation Trial Of QPI-1007 Delivered By A Single Intravitreal (IVT) Injection To Subjects With Low Visual Acuity And Acute Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)
Creator Bradley J. Katz, MD, PhD
Affiliation John A. Moran Eye Center
Subject Ischemic Optic Neuropathy; Intravitreal Injection; Caspase 2; siRNA; QPI-1007
Description Subjects with stable low vision due to posterior segment pathology and subjects with acute onset NAION were enrolled in a 2 strata, Phase I, multi-center, open-label, and dose escalation study to determine safety, tolerability, and the structural and functional changes after single IVT injection of QPI-1007, a synthetic, chemically modified siRNA that inhibits expression of caspase 2.
Date 2013-02-12
Language eng
Format application/pdf
Format Creation Microsoft PowerPoint
Type Text
Source 2013 North American Neuro-Ophthalmology Society Annual Meeting
Relation is Part of NANOS 2013: Platform Presentations (Session II)
Collection Neuro-Ophthalmology Virtual Education Library: NANOS Annual Meeting Collection: https://novel.utah.edu/collection/nanos-annual-meeting-collection/
Publisher North American Neuro-Ophthalmology Society
Holding Institution Spencer S. Eccles Health Sciences Library, University of Utah
Rights Management Copyright 2013. For further information regarding the rights to this collection, please visit: https://NOVEL.utah.edu/about/copyright
ARK ark:/87278/s6k109xz
Setname ehsl_novel_nam
ID 183229
Reference URL https://collections.lib.utah.edu/ark:/87278/s6k109xz
Back to Search Results